Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

E2F site in the essential promoter region does not confer S phase-specific transcription of the ABCC10 gene in human prostate cancer cells.

Dabrowska M, Sirotnak FM.

Acta Biochim Pol. 2017;64(2):371-374. doi: 10.18388/abp.2017_1521. Epub 2017 Jun 13.

2.

Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.

Azzoli CG, Patel JD, Krug LM, Miller V, James L, Kris MG, Ginsberg M, Subzwari S, Tyson L, Dunne M, May J, Huntington M, Saunders M, Sirotnak FM.

J Thorac Oncol. 2011 Nov;6(11):1915-22. doi: 10.1097/JTO.0b013e31822adb19.

3.

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM.

J Clin Oncol. 2009 Jan 10;27(2):264-70. doi: 10.1200/JCO.2008.17.4656. Epub 2008 Dec 1.

4.

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.

Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM.

Clin Cancer Res. 2007 May 1;13(9):2692-8.

5.

Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.

Krug LM, Heelan RT, Kris MG, Venkatraman E, Sirotnak FM.

J Thorac Oncol. 2007 Apr;2(4):317-20.

6.

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA.

Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75. Epub 2006 Aug 1.

PMID:
16896930
7.
8.

Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.

Lee MD, She Y, Soskis MJ, Borella CP, Gardner JR, Hayes PA, Dy BM, Heaney ML, Philips MR, Bornmann WG, Sirotnak FM, Scheinberg DA.

J Clin Invest. 2004 Oct;114(8):1107-16.

10.

Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.

Sirotnak FM, She Y, Khokhar NZ, Hayes P, Gerald W, Scher HI.

Mol Carcinog. 2004 Nov;41(3):150-63.

PMID:
15390081
11.

The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.

Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, Haimovitz-Friedman A, Schwartz GK.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6052-61.

12.

A new human peptide deformylase inhibitable by actinonin.

Lee MD, Antczak C, Li Y, Sirotnak FM, Bornmann WG, Scheinberg DA.

Biochem Biophys Res Commun. 2003 Dec 12;312(2):309-15.

PMID:
14637138
13.

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.

She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, Kris MG, Sirotnak FM.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3773-8.

14.
15.

10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.

Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, Sirotnak FM.

Clin Cancer Res. 2003 Jun;9(6):2072-8.

16.

Studies with ZD1839 in preclinical models.

Sirotnak FM.

Semin Oncol. 2003 Feb;30(1 Suppl 1):12-20. Review.

PMID:
12644980
18.

Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.

Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK.

Cancer Res. 2002 Jul 15;62(14):3950-5.

20.
21.

Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.

Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK.

Clin Cancer Res. 2001 Dec;7(12):4209-19.

24.

Synthesis and antifolate evaluation of the aminopterin analogue with a bicyclo.

Reynolds RC, Johnson CA, Piper JR, Sirotnak FM.

Eur J Med Chem. 2001 Mar;36(3):237-42.

PMID:
11337102
25.

Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.

Laurie SA, Pfister DG, Kris MG, Tong WP, Chronowski G, Pisters KM, Heelan RT, Sirotnak FM.

Clin Cancer Res. 2001 Mar;7(3):501-9.

26.
27.

Adaptive regulation of intestinal folate uptake: effect of dietary folate deficiency.

Said HM, Chatterjee N, Haq RU, Subramanian VS, Ortiz A, Matherly LH, Sirotnak FM, Halsted C, Rubin SA.

Am J Physiol Cell Physiol. 2000 Dec;279(6):C1889-95.

28.

Molecular cloning of the murine cMOAT ATPase.

Fritz F, Chen J, Hayes P, Sirotnak FM.

Biochim Biophys Acta. 2000 Jul 24;1492(2-3):531-6.

PMID:
11004524
29.
30.

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.

Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, Leon L, Leung D, Kelly J, Grant SC, Sirotnak FM.

Clin Cancer Res. 2000 Sep;6(9):3493-8. Erratum in: Clin Cancer Res 2001 Apr;7(4):1102.

31.

A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility.

Sirotnak FM, Sepp-Lorenzino L, Kohl NE, Rosen N, Scher HI.

Cancer Chemother Pharmacol. 2000;46(1):79-83.

PMID:
10912583
32.
33.

Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium.

Chancy CD, Kekuda R, Huang W, Prasad PD, Kuhnel JM, Sirotnak FM, Roon P, Ganapathy V, Smith SB.

J Biol Chem. 2000 Jul 7;275(27):20676-84.

35.
36.

RESPONSE: Re: Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo.

Sirotnak FM.

J Natl Cancer Inst. 1999 Dec 1;91(23):2049-2050. No abstract available.

PMID:
10580035
37.

Carrier-mediated membrane transport of folates in mammalian cells.

Sirotnak FM, Tolner B.

Annu Rev Nutr. 1999;19:91-122. Review.

PMID:
10448518
38.

Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.

Rigas JR, Kris MG, Miller VA, Pisters KM, Heelan RT, Grant SC, Fennelly DW, Chou TC, Sirotnak FM.

Ann Oncol. 1999 May;10(5):601-3.

PMID:
10416013
39.

Enhancing cytotoxic sensitivity of tumor cells to antifolates: another opportunity for gene therapy?

Sirotnak FM.

J Natl Cancer Inst. 1999 Jul 21;91(14):1178-9. No abstract available.

PMID:
10413407
40.

Organization and structure of the mouse gamma-glutamyl hydrolase gene and the functional identification of its promoter.

Esaki T, Masumoto N, Hayes P, Chen J, Sirotnak FM.

Gene. 1999 Jun 24;234(1):93-100.

PMID:
10393243
41.
42.
43.

A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.

Sirotnak FM, DeGraw JI, Colwell WT, Piper JR.

Cancer Chemother Pharmacol. 1998;42(4):313-8.

PMID:
9744777
44.

Chromosomal localization of the murine RFC-1 gene encoding a folate transporter and its amplification in an antifolate resistant variant overproducing the transporter.

Roy K, Chiao JH, Spengler BA, Tolner B, Yang CH, Biedler JL, Sirotnak FM.

Cancer Genet Cytogenet. 1998 Aug;105(1):29-38.

PMID:
9689927
47.

RFC-1 gene expression regulates folate absorption in mouse small intestine.

Chiao JH, Roy K, Tolner B, Yang CH, Sirotnak FM.

J Biol Chem. 1997 Apr 25;272(17):11165-70.

48.
49.

The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract.

Jaton JC, Roulin K, Rose K, Sirotnak FM, Lewenstein A, Brunner G, Fankhauser CP, Burger U.

J Nat Prod. 1997 Apr;60(4):356-60.

PMID:
9134744

Supplemental Content

Loading ...
Support Center